High levels of lipoprotein (a)[Lp (a)], an apoB100-containing lipoprotein, are an independent
and causal risk factor for atherosclerotic cardiovascular diseases through mechanisms …

Evidence on the validity of drug targets from randomized trials is reliable but typically
expensive and slow to obtain. In contrast, evidence from conventional observational …

Background Lipoprotein (a) is a presumed risk factor for atherosclerotic cardiovascular
disease. Olpasiran is a small interfering RNA that reduces lipoprotein (a) synthesis in the …

Importance Epidemiological and genetic data have implicated lipoprotein (a) as a potentially
modifiable risk factor for atherosclerotic disease and aortic stenosis, but there are no …

Background Lipoprotein (a) concentration is associated with cardiovascular events.
Alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, lowers lipoprotein (a) …

Rates of atherosclerotic cardiovascular diseases (CVD) in the Western world have
spectacularly decreased over the past 50 years. However, a substantial proportion of high …

Background: Lipoprotein (a)[Lp (a)] levels predict the risk of myocardial infarction (MI) in
populations of European ancestry; however, few data are available for other ethnic groups …

Abstract Lipoprotein (a), Lp (a), is a modified atherogenic low-density lipoprotein particle that
contains apolipoprotein (a). Its levels are highly heritable and variable in the population …

Importance Lipoprotein (a) is a highly heritable biomarker independently associated with
atherosclerotic cardiovascular disease (ASCVD). It is unclear whether measured lipoprotein …

Abstract Background: Lipoprotein (a)[Lp (a)] is a causal risk factor for cardiovascular
diseases that has no established therapy. The attribute of Lp (a) that affects cardiovascular …